Hemophilia A (severe or moderately severe)
Showing 1 - 25 of >10,000
Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)
Not yet recruiting
- Hemophilia B Without Inhibitor
- Low dose KL001
- +2 more
- (no location specified)
Nov 5, 2023
Hemophilia B Trial (CSL222 (AAV5-hFIXco-Padua))
Not yet recruiting
- Hemophilia B
- CSL222 (AAV5-hFIXco-Padua)
- (no location specified)
Aug 14, 2023
Hemophilia A Trial in Little Rock (ASC618)
Recruiting
- Hemophilia A
- ASC618
-
Little Rock, ArkansasArkansas Children's Hospital
Jan 30, 2023
Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
Active, not recruiting
- Hemophilia B
- AAV5-hFIX
-
Berlin, Germany
- +5 more
Jan 17, 2023
Hemophilia A, Hemophilia B Trial in Korea, Republic of, South Africa, Taiwan (marstacimab)
Recruiting
- Hemophilia A
- Hemophilia B
-
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
- +3 more
Jan 18, 2023
Hemophilia Trial in Tianjin (KN057 dose?, KN057 dose ?, KN057 dose ?)
Recruiting
- Hemophilia
- KN057 doseⅠ
- +2 more
-
Tianjin, Tianjin, China
- +1 more
Jul 20, 2022
Hemophilia A Trial in United Kingdom, United States (SIG-001)
Terminated
- Hemophilia A
- SIG-001
-
Indianapolis, Indiana
- +5 more
Nov 7, 2022
Hemophilia B Trial in Worldwide (AAV5-hFIXco-Padua)
Active, not recruiting
- Hemophilia B
- AAV5-hFIXco-Padua
- Factor IX (FIX)
-
Phoenix, Arizona
- +32 more
Sep 26, 2022
Hemophilia B Trial in United States (AAV5-hFIXco-Padua (AMT-061))
Active, not recruiting
- Hemophilia B
- AAV5-hFIXco-Padua (AMT-061)
-
Los Angeles, California
- +3 more
May 17, 2022
Hemophilia A Trial in Worldwide (PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy)
Active, not recruiting
- Hemophilia A
- PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
-
Mountain View, California
- +34 more
Jan 26, 2022
Hemophilia B, Hemophilia A Trial in Worldwide (Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement
Recruiting
- Hemophilia B
- Hemophilia A
- Standard of Care FIX Replacement therapy
- Standard of Care FVIII Replacement therapy
-
Palo Alto, California
- +77 more
Dec 29, 2022
Hemophilia A Trial in Toronto (Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins
Completed
- Hemophilia A
- Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
-
Toronto, Ontario, CanadaHospital for Sick Children
May 3, 2021
Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)
Not yet recruiting
- Hemophilia B Without Inhibitor
- Low dose KL001
- +2 more
- (no location specified)
Nov 5, 2023
Severe Hemophilia A Without Inhibitor, Joint Bleed Trial in Bangkok ("Emicizumab", "HEMLIBRA®")
Recruiting
- Severe Hemophilia A Without Inhibitor
- Joint Bleed
- "Emicizumab", "HEMLIBRA®"
-
Bangkok, ThailandKing Chulalongkorn Memorial hospital
Nov 25, 2023
Dynamics of Anti-factor VIII Antibody Signature During Treatment
Not yet recruiting
- Severe Hemophilia A
- +2 more
- no interventions
- (no location specified)
Apr 4, 2023
Bleeding Rates Among Severe Hemophilia A on Emicizumab
Not yet recruiting
- Hemophilia A
-
Newark, New JerseyNewark Beth Israel Medical Center
Oct 26, 2023
Hemophilia A Trial in Worldwide (Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80
Completed
- Hemophilia A
- Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)
-
Sofia, Bulgaria
- +4 more
Apr 28, 2021
Hemophilia A Trial in Worldwide (Antihemophilic factor, recombinant, manufactured protein-free)
Completed
- Hemophilia A
- Antihemophilic factor, recombinant, manufactured protein-free
-
Los Angeles, California
- +28 more
Apr 28, 2021
Severe Hemophilia Non-Interventional Study
Not yet recruiting
- Hemophilia A
- Hemophilia B
- No Intervention
-
Rzeszów, Podkarpackie, Poland
- +2 more
Dec 8, 2022